IDH1 R132 mutations (~6-10% of AML). Ivosidenib monotherapy (AGILE, Montesinos et al. NEJ...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-IDH1-R132H-AML |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-AML |
| Sources | SRC-CIVIC SRC-ELN-AML-2022 SRC-ESMO-AML-2020 SRC-NCCN-AML-2025 |
Actionability Facts
| Biomarker | BIO-IDH-MUTATION |
|---|---|
| Variant | IDH1 R132H |
| Disease | DIS-AML |
| ESCAT tier | IA |
| Recommended combinations | ivosidenib monotherapy, ivosidenib + azacitidine (1L unfit), olutasidenib monotherapy, ivosidenib + 7+3 (frontline fit, in trials) |
| Evidence summary | IDH1 R132 mutations (~6-10% of AML). Ivosidenib monotherapy (AGILE, Montesinos et al. NEJM 2022 — combo with azacitidine; AG120-C-001 — monotherapy in R/R) FDA-approved. Ivosidenib + azacitidine (1L unfit, AGILE) doubles OS vs azacitidine alone. |
Notes
ESCAT IA. Differentiation syndrome class AE — prophylactic dexamethasone protocol per ELN. Companion dx: Abbott RealTime IDH1.
Used By
No reverse references found in the YAML corpus.